Eli Lilly and Company $LLY Shares Bought by Corient Private Wealth LLC

Corient Private Wealth LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.5% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 620,126 shares of the company’s stock after acquiring an additional 20,698 shares during the quarter. Eli Lilly and Company makes up about 0.7% of Corient Private Wealth LLC’s investment portfolio, making the stock its 22nd biggest position. Corient Private Wealth LLC’s holdings in Eli Lilly and Company were worth $483,407,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in LLY. Capital A Wealth Management LLC lifted its position in shares of Eli Lilly and Company by 20.0% in the 2nd quarter. Capital A Wealth Management LLC now owns 102 shares of the company’s stock worth $80,000 after buying an additional 17 shares during the last quarter. Caldwell Trust Co acquired a new stake in Eli Lilly and Company during the second quarter worth about $17,214,000. Silicon Valley Capital Partners lifted its holdings in Eli Lilly and Company by 12.3% in the second quarter. Silicon Valley Capital Partners now owns 18,121 shares of the company’s stock worth $14,126,000 after acquiring an additional 1,990 shares during the last quarter. WT Wealth Management boosted its stake in Eli Lilly and Company by 1.8% in the second quarter. WT Wealth Management now owns 814 shares of the company’s stock valued at $635,000 after acquiring an additional 14 shares during the period. Finally, NWF Advisory Services Inc. grew its holdings in shares of Eli Lilly and Company by 103.1% during the second quarter. NWF Advisory Services Inc. now owns 1,974 shares of the company’s stock valued at $1,539,000 after purchasing an additional 1,002 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on LLY. Guggenheim reaffirmed a “buy” rating and issued a $1,163.00 price objective on shares of Eli Lilly and Company in a report on Wednesday, December 3rd. National Bankshares set a $1,286.00 price objective on Eli Lilly and Company in a research report on Monday, December 1st. UBS Group increased their price objective on Eli Lilly and Company from $895.00 to $1,080.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Berenberg Bank lifted their target price on Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a research note on Tuesday, December 2nd. Finally, Truist Financial boosted their price target on Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the stock a “buy” rating in a research report on Wednesday, November 19th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $1,128.55.

Eli Lilly and Company Stock Performance

LLY opened at $1,062.67 on Tuesday. The company has a market capitalization of $1.00 trillion, a price-to-earnings ratio of 51.99, a price-to-earnings-growth ratio of 1.14 and a beta of 0.37. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,111.99. The business has a 50 day moving average price of $943.82 and a two-hundred day moving average price of $822.76.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. During the same period last year, the firm earned $1.18 EPS. The firm’s revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.